65 reports of this reaction
1.5% of all ARSENIC TRIOXIDE reports
#16 most reported adverse reaction
ASPARTATE AMINOTRANSFERASE INCREASED is the #16 most commonly reported adverse reaction for ARSENIC TRIOXIDE, manufactured by Cephalon, LLC. There are 65 FDA adverse event reports linking ARSENIC TRIOXIDE to ASPARTATE AMINOTRANSFERASE INCREASED. This represents approximately 1.5% of all 4,344 adverse event reports for this drug.
Patients taking ARSENIC TRIOXIDE who experience aspartate aminotransferase increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASPARTATE AMINOTRANSFERASE INCREASED is a less commonly reported adverse event for ARSENIC TRIOXIDE, but still significant enough to appear in the safety profile.
In addition to aspartate aminotransferase increased, the following adverse reactions have been reported for ARSENIC TRIOXIDE:
The following drugs have also been linked to aspartate aminotransferase increased in FDA adverse event reports:
ASPARTATE AMINOTRANSFERASE INCREASED has been reported as an adverse event in 65 FDA reports for ARSENIC TRIOXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASPARTATE AMINOTRANSFERASE INCREASED accounts for approximately 1.5% of all adverse event reports for ARSENIC TRIOXIDE, making it a notable side effect.
If you experience aspartate aminotransferase increased while taking ARSENIC TRIOXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.